Search for Terms or Answers
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me? Feel free to use this in your own
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
There is no doubt it is an incredibly exciting time to be tackling obesity-related diseases, like many rheumatic diseases appear to be, to some extent. However, deep down, a part of us must dread adding yet another conversation to a crowded consultation. One of two things has to happen: we
That promised land of substantive weight loss comes within it the illusion of better disease control and, for inflammatory arthritis patients, the possibility of reducing the burden of regular medicines - often driven by the patient, with or without telling you. It is a dream worth aspiring to
When Ms. RS came into my clinic for a new patient evaluation, she was suffering from highly active skin disease, joint swelling, pain and poor mobility. Her body mass index was 46, indicating class III obesity. A treatment plan focused solely on her inflammatory disease without addressing her
Annals of Internal Medicine has published the updated 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines on adult Overweight and Obesity management. Here is a review of the guidelines, including five key takeaways for rheumatologists.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Obesity is a clinically important comorbidity in psoriasis and psoriatic arthritis. Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic therapies. Intentional weight loss should be considered an
A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.
The Endocrine Society has published a scientific statement reframing obesity as a heterogeneous, chronically dysregulated fat-mass disorder, the biology of which is being tested effectively by GLP-1/GIP receptor agonists. Is this precision-medicine? We await long-term safety data, while
As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to pharmacotherapy - a reversal of the traditional model. This has with direct
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
The American College of Rheumatology (ACR) has released updated clinical guidance for the treatment and management of osteoarthritis (OA) of the knee, hip, and hand. The evidence-based recommendations update the 2019 ACR/Arthritis Foundation guideline and are designed to support individualized,
The costs of GLP-1 agonists must come down in order to make these treatments available to the people who need them - including many people with rheumatologic diseases.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
